glp-1 agonist oral Orforglipron, an Small-Molecule Receptor for Obesity November 5, 2025 DOI: 10.1056/NEJMdo008238 New for the treatment of obesity - and so many additional indications being studied Danuglipron: An Oral GLP-1R Agonist

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

Discover how GLP-1 and GLP-1/GIP therapies (semaglutide and tirzepatide) influence body composition

Limited head-to-head studies compare established glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is), and sodium-glucose co-transporter-2 inhibitors (SGLT-2is) to insulin in the management of uncontrolled type 2 diabetes mellitus (T2DM)

Ozempic has become a buzzword in weight loss and type 2 diabetes management

Supports overall daily wellness

| 228 comments on LinkedIn